{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:23:21Z","timestamp":1788323001925,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD80, which regulates T cell activation, may provide a differential diagnostic marker between minimal change disease (MCD) and other renal diseases, including focal segmental glomerular sclerosis (FSGS). However, recent reports show contrasting results. Therefore, we evaluated the utility of urinary CD80 as a diagnostic biomarker. We collected 65 urine samples from 55 patients with MCD (n\u2009=\u200931), FSGS (n\u2009=\u20094), inherited nephrotic syndrome (n\u2009=\u20094), Alport syndrome (n\u2009=\u20095) and other glomerular diseases (n\u2009=\u200911), and control samples (n\u2009=\u200930). We measured urinary CD80 levels by ELISA. Urinary CD80 (ng\/gCr) (median, interquartile range) levels were significantly higher in patients with MCD in relapse (91.5, 31.1\u2013356.0), FSGS (376.2, 62.7\u20131916.0), and inherited nephrotic syndrome (220.1, 62.9\u2013865.3), than in patients with MCD in remission (29.5, 21.7\u201352.8) (p\u2009&lt;\u20090.05). Elevation of urinary CD80 was observed, even in patients with inherited nephrotic syndrome unrelated to T cell activation. Additionally, urinary CD80 was positively correlated with urinary protein levels. Our results suggest that urinary CD80 is unreliable as a differential diagnostic marker between MCD in relapse and FSGS or inherited kidney diseases. Increased urinary CD80 excretion was present in all patients with active kidney disease.<\/jats:p>","DOI":"10.1038\/s41598-018-35798-2","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T16:43:20Z","timestamp":1542645800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The utility of urinary CD80 as a diagnostic marker in patients with renal diseases"],"prefix":"10.1038","volume":"8","author":[{"given":"Shogo","family":"Minamikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Maeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"China","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ninchoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"35798_CR1","first-page":"43","volume":"34","author":"JP Caulfield","year":"1976","unstructured":"Caulfield, J. P. & Farquhar, R. J. MG. Alterations of the glomerular epithelium in acute aminonucleoside nephrosis. Evidence for formation of occluding junctions and epithelial cell detachment. Lab Invest 34, 43\u201359 (1976).","journal-title":"Lab Invest"},{"key":"35798_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ki.1975.105","volume":"8","author":"GB Ryan","year":"1975","unstructured":"Ryan, G. B. & Karnovsky, M. J. An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. Kidney International 8, 219\u2013232, https:\/\/doi.org\/10.1038\/ki.1975.105 (1975).","journal-title":"Kidney International"},{"key":"35798_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy, A. A. & Symons, J. M. Nephrotic syndrome in childhood. The Lancet 362, 629\u2013639, https:\/\/doi.org\/10.1016\/s0140-6736(03)14184-0 (2003).","journal-title":"The Lancet"},{"key":"35798_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub, R. J. Pathogenesis of lipoid nephrosis- A disorder of T-cell function. Lancet 2, 556\u2013603 (1974).","journal-title":"Lancet"},{"key":"35798_CR5","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1681\/ASN.2014030267","volume":"25","author":"C Mace","year":"2014","unstructured":"Mace, C. & Chugh, S. S. Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics. J Am Soc Nephrol 25, 2393\u20132398, https:\/\/doi.org\/10.1681\/ASN.2014030267 (2014).","journal-title":"J Am Soc Nephrol"},{"key":"35798_CR6","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2215\/CJN.01190210","volume":"5","author":"AK Buscher","year":"2010","unstructured":"Buscher, A. K. et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 5, 2075\u20132084, https:\/\/doi.org\/10.2215\/CJN.01190210 (2010).","journal-title":"Clin J Am Soc Nephrol"},{"key":"35798_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2215\/CJN.07370715","volume":"11","author":"AK Buscher","year":"2016","unstructured":"Buscher, A. K. et al. Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol 11, 245\u2013253, https:\/\/doi.org\/10.2215\/CJN.07370715 (2016).","journal-title":"Clin J Am Soc Nephrol"},{"key":"35798_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/35105024","volume":"1","author":"Maria-Luisa Alegre","year":"2001","unstructured":"Alegre, Maria-Luisa, Frauwirth, K. A. & Thompson, C. B. T-CELL REGULATION BY CD28 AND CTLA-4. Nature Reviews Immunology 1, 220\u2013228 (2001).","journal-title":"Nature Reviews Immunology"},{"key":"35798_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1046\/j.1523-1747.2000.00997.x","volume":"114","author":"P Wakem","year":"2000","unstructured":"Wakem, P. et al. Allergens and irritants transcriptionally upregulate CD80 gene expression in human keratinocytes. J Invest Dermatol 114, 1085\u20131092, https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00997.x (2000).","journal-title":"J Invest Dermatol"},{"key":"35798_CR10","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.4049\/jimmunol.166.11.6491","volume":"166","author":"M Donepudi","year":"2001","unstructured":"Donepudi, M., Raychaudhuri, P., Bluestone, J. A. & Mokyr, M. B. Mechanism of Melphalan-Induced B7-1 Gene Expression in P815 Tumor Cells. The Journal of Immunology 166, 6491\u20136499, https:\/\/doi.org\/10.4049\/jimmunol.166.11.6491 (2001).","journal-title":"The Journal of Immunology"},{"key":"35798_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/ndt\/gfs543","volume":"28","author":"T Ishimoto","year":"2013","unstructured":"Ishimoto, T. et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol Dial Transplant 28, 1439\u20131446, https:\/\/doi.org\/10.1093\/ndt\/gfs543 (2013).","journal-title":"Nephrol Dial Transplant"},{"key":"35798_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ki.2010.143","volume":"78","author":"EH Garin","year":"2010","unstructured":"Garin, E. H. et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78, 296\u2013302, https:\/\/doi.org\/10.1038\/ki.2010.143 (2010).","journal-title":"Kidney Int"},{"key":"35798_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1681\/ASN.2007080836","volume":"20","author":"EH Garin","year":"2009","unstructured":"Garin, E. H. et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20, 260\u2013266, https:\/\/doi.org\/10.1681\/ASN.2007080836 (2009).","journal-title":"J Am Soc Nephrol"},{"key":"35798_CR14","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/jci20402","volume":"113","author":"J Reiser","year":"2004","unstructured":"Reiser, J. et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113, 1390\u20131397, https:\/\/doi.org\/10.1172\/jci20402 (2004).","journal-title":"J Clin Invest"},{"key":"35798_CR15","doi-asserted-by":"publisher","first-page":"F335","DOI":"10.1152\/ajprenal.00510.2015","volume":"310","author":"R Novelli","year":"2016","unstructured":"Novelli, R., Gagliardini, E., Ruggiero, B., Benigni, A. & Remuzzi, G. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? Am J Physiol Renal Physiol 310, F335\u2013341, https:\/\/doi.org\/10.1152\/ajprenal.00510.2015 (2016).","journal-title":"Am J Physiol Renal Physiol"},{"key":"35798_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1053\/j.ajkd.2014.07.023","volume":"64","author":"CP Larsen","year":"2014","unstructured":"Larsen, C. P., Messias, N. C. & Walker, P. D. B7-1 immunostaining in proteinuric kidney disease. Am J Kidney Dis 64, 1001\u20131003, https:\/\/doi.org\/10.1053\/j.ajkd.2014.07.023 (2014).","journal-title":"Am J Kidney Dis"},{"key":"35798_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1681\/ASN.2015080947","volume":"27","author":"DJ Salant","year":"2016","unstructured":"Salant, D. J. Podocyte Expression of B7-1\/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept? J Am Soc Nephrol 27, 963\u2013965, https:\/\/doi.org\/10.1681\/ASN.2015080947 (2016).","journal-title":"J Am Soc Nephrol"},{"key":"35798_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00467-014-2915-3","volume":"30","author":"C Ling","year":"2015","unstructured":"Ling, C. et al. Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol 30, 309\u2013316, https:\/\/doi.org\/10.1007\/s00467-014-2915-3 (2015).","journal-title":"Pediatr Nephrol"},{"key":"35798_CR19","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1080\/10428190410001712199","volume":"45","author":"BD Hock","year":"2004","unstructured":"Hock, B. D. et al. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 45, 2111\u20132118 (2004).","journal-title":"Leuk Lymphoma"},{"key":"35798_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00467-013-2679-1","volume":"29","author":"G Cara-Fuentes","year":"2014","unstructured":"Cara-Fuentes, G. et al. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol 29, 1363\u20131371, https:\/\/doi.org\/10.1007\/s00467-013-2679-1 (2014).","journal-title":"Pediatr Nephrol"},{"key":"35798_CR21","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00467-014-2874-8","volume":"29","author":"G Cara-Fuentes","year":"2014","unstructured":"Cara-Fuentes, G., Wasserfall, C. H., Wang, H., Johnson, R. J. & Garin, E. H. Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis? Pediatr Nephrol 29, 2333\u20132340, https:\/\/doi.org\/10.1007\/s00467-014-2874-8 (2014).","journal-title":"Pediatr Nephrol"},{"key":"35798_CR22","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00467-017-3613-8","volume":"32","author":"OP Mishra","year":"2017","unstructured":"Mishra, O. P. et al. Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome. Pediatr Nephrol 32, 1355\u20131361, https:\/\/doi.org\/10.1007\/s00467-017-3613-8 (2017).","journal-title":"Pediatr Nephrol"},{"key":"35798_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3265\/Nefrologia.pre2013.Jun.12085","volume":"33","author":"G Cara-Fuentes","year":"2013","unstructured":"Cara-Fuentes, G. et al. CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation. Nefrologia 33, 727\u2013731, https:\/\/doi.org\/10.3265\/Nefrologia.pre2013.Jun.12085 (2013).","journal-title":"Nefrologia"},{"key":"35798_CR24","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/art.1780330803","volume":"33","author":"A John","year":"1990","unstructured":"John, A. & Mills, M. D. et al. The American College of Rheumatology 1990 criteria for the classification of henoch-scho\u0308nlein purpura Authors. Arthritis Rheum. 33, 1068\u20131073 (1990).","journal-title":"Arthritis Rheum."},{"key":"35798_CR25","first-page":"249","volume":"24","author":"P Royer","year":"1967","unstructured":"Royer, P., Courtecuisse, H. R. & Leclerc, V. F. Bilateral renal hypoplasia with oligonephronia. (Study of 21 cases). Arch Fr Pediatr. 24, 249\u2013268 (1967).","journal-title":"Arch Fr Pediatr."},{"key":"35798_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(70)91268-7","volume":"295","author":"RHR White","year":"1970","unstructured":"White, R. H. R., Glasgow, E. F. & Mills R. J. Clinicopathological study of nephrotic syndrome in childhood. Lancet 295, 1353\u20131359 (1970).","journal-title":"Lancet"},{"key":"35798_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10157-014-0995-9","volume":"18","author":"T Igarashi","year":"2014","unstructured":"Igarashi, T. et al. Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol 18, 525\u2013557, https:\/\/doi.org\/10.1007\/s10157-014-0995-9 (2014).","journal-title":"Clin Exp Nephrol"},{"key":"35798_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/ki.2015.252","volume":"88","author":"R Magistroni","year":"2015","unstructured":"Magistroni, R., D\u2019Agati, V. D., Appel, G. B. & Kiryluk, K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 88, 974\u2013989, https:\/\/doi.org\/10.1038\/ki.2015.252 (2015).","journal-title":"Kidney Int"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35798-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T15:06:21Z","timestamp":1720796781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35798-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35798"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35798-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17322"}}